We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.

Metastatic castration-resistant prostate cancer (mCRPC) refers to cancer that has spread (metastasized) beyond the prostate gland and for which hormone therapy is no longer effective in stopping or slowing the disease.

For patients with mCRPC, Exact Sciences offers the Oncotype DX AR-V7 Nucleus Detect® assay, a liquid biopsy blood test to help patients quickly and confidently determine whether they'll respond to AR-targeted therapies.

The only predictive and prognostic test for patients with mCRPC, the AR-V7 Nucleus Detect test:

  • accurately identifies patients who will not benefit from AR-targeted therapies,1-2
  • is predictive of improved overall survival with taxanes versus AR-targeted therapies,1-2
  • provides easy-to-interpret results (a positive or negative result).




1Scher et al. JAMA Oncol. 2016.

27Scher et al. JAMA Oncol. 2018.